$INCY News

Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3

How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis

Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder

BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $112

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Incyte to Report Second Quarter Financial Results

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $99

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion

INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura

Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?

Incyte: New Catalysts Support Another Leg Higher

HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target

Incyte (INCY) Stock After 66% One-Year Rally Is The Market Too Optimistic Now

Incyte (INCY) Wins EU Backing For Opzelura As Pipeline Data Builds Across Four Drugs

UBS Maintains Neutral on Incyte, Raises Price Target to $113

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Incyte Announces EMA CHMP Positive Opinion Recommending Approval Of Opzelura Cream For Moderate Atopic Dermatitis; Application Now Referred To European Commission For Final Action